490-31-3 Usage
Description
ROBINETIN, also known as pentahydroxyflavone, is a flavone compound characterized by the presence of hydroxy groups at positions 3, 7, 3', 4', and 5'. It is a naturally occurring flavonoid with potential applications in various industries due to its unique chemical structure and properties.
Uses
Used in Pharmaceutical Industry:
ROBINETIN is used as a pharmaceutical agent for its potential therapeutic effects. ROBINETIN's hydroxy groups allow it to interact with various biopolymers and macromolecules, making it a promising candidate for the development of new drugs and therapies.
Used in Cosmetic Industry:
In the cosmetic industry, ROBINETIN is used as an active ingredient for its antioxidant and anti-inflammatory properties. It can be incorporated into skincare products to help protect the skin from environmental stressors and promote a healthy, youthful appearance.
Used in Food and Beverage Industry:
ROBINETIN can be used in the food and beverage industry as a natural additive due to its antioxidant properties. It can help extend the shelf life of products by preventing oxidation and rancidity, as well as contribute to the overall flavor and color of certain food items.
Used in Agricultural Industry:
In agriculture, ROBINETIN can be utilized as a natural pesticide or fungicide due to its antimicrobial properties. It can help protect crops from various diseases and pests, promoting healthier growth and increased yield.
Used in Research and Development:
ROBINETIN is also used in research and development for its potential applications in various fields. Scientists and researchers can study the compound's interactions with different molecules and biopolymers to develop new drugs, materials, and technologies.
Check Digit Verification of cas no
The CAS Registry Mumber 490-31-3 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 4,9 and 0 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 490-31:
(5*4)+(4*9)+(3*0)+(2*3)+(1*1)=63
63 % 10 = 3
So 490-31-3 is a valid CAS Registry Number.
InChI:InChI=1/C15H10O7/c16-7-1-2-8-11(5-7)22-15(14(21)12(8)19)6-3-9(17)13(20)10(18)4-6/h1-5,16-18,20-21H
490-31-3Relevant articles and documents
Profiling of flavonol derivatives for the development of antitrypanosomatidic drugs
Borsari, Chiara,Lucian, Rosaria,Pozzi, Cecilia,Poehner, Ina,Henrich, Stefan,Trande, Matteo,Cordeiro-Da-silva, Anabela,Santarem, Nuno,Baptista, Catarina,Tait, Annalisa,Di Pisa, Flavio,Iacono, Lucia Dello,Landi, Giacomo,Gul, Sheraz,Wolf, Markus,Kuzikov, Maria,Ellinger, Bernhard,Reinshagen, Jeanette,Witt, Gesa,Gribbon, Philip,Kohler, Manfred,Keminer, Oliver,Behrens, Birte,Costantino, Luca,Nevado, Paloma Tejera,Bifeld, Eugenia,Eick, Julia,Clos, Joachim,Torrado, Juan,Jiménez-Antón, María D.,Corral, María J.,Alunda, José Ma,Pellati, Federica,Wade, Rebecca C.,Ferrari, Stefania,Mangani, Stefano,Costi, Maria Paola
, p. 7598 - 7616 (2016/09/04)
Flavonoids represent a potential source of new antitrypanosomatidic leads. Starting from a library of natural products, we combined target-based screening on pteridine reductase 1 with phenotypic screening on Trypanosoma brucei for hit identification. Flavonols were identified as hits, and a library of 16 derivatives was synthesized. Twelve compounds showed EC50 values against T. brucei below 10 μM. Four X-ray crystal structures and docking studies explained the observed structure-activity relationships. Compound 2 (3,6-dihydroxy-2-(3-hydroxyphenyl)-4H-chromen-4-one) was selected for pharmacokinetic studies. Encapsulation of compound 2 in PLGA nanoparticles or cyclodextrins resulted in lower in vitro toxicity when compared to the free compound. Combination studies with methotrexate revealed that compound 13 (3-hydroxy-6-methoxy-2-(4-methoxyphenyl)-4H-chromen-4-one) has the highest synergistic effect at concentration of 1.3 μM, 11.7-fold dose reduction index and no toxicity toward host cells. Our results provide the basis for further chemical modifications aimed at identifying novel antitrypanosomatidic agents showing higher potency toward PTR1 and increased metabolic stability.